ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for RNAC

Stock NameCartesian Therapeutics Inc.
TickerRNAC(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS8162121045

Show aggregate RNAC holdings

News associated with RNAC

Biotech Stocks Rally After Hours On Friday Ahead Of Key Clinical Trial Updates
(RTTNews) - Several clinical-stage biotech companies saw strong after-hours momentum on Friday, driven by upcoming trial data releases and pipeline updates. - 2025-09-22 01:38:16
Wedbush Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC)
Analysts at Wedbush assumed coverage on shares of Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) in a report released on Wednesday, Marketbeat reports. The brokerage set an “outperform” rating and a $38.00 price target on the stock. Wedbush’s target price suggests a potential upside of 180.65% from the company’s previous close. Several other equities research […] - 2025-07-11 02:50:53
Rhumbline Advisers Increases Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)
Rhumbline Advisers increased its stake in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) by 27.5% during the first quarter, Holdings Channel.com reports. The institutional investor owned 13,006 shares of the company’s stock after buying an additional 2,805 shares during the quarter. Rhumbline Advisers’ holdings in Cartesian Therapeutics were worth $171,000 as of its […] - 2025-06-26 04:55:01
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.50
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among analysts […] - 2025-05-23 03:14:53
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has received an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target […] - 2025-04-30 03:09:00
Corebridge Financial Inc. Raises Stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)
Corebridge Financial Inc. boosted its holdings in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) by 32.6% during the 4th quarter, Holdings Channel reports. The firm owned 5,122 shares of the company’s stock after buying an additional 1,258 shares during the period. Corebridge Financial Inc.’s holdings in Cartesian Therapeutics were worth $92,000 at the […] - 2025-04-16 04:28:52
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from HC Wainwright
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 286.10% from the company’s previous close. Several […] - 2025-04-11 05:17:00
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average Price Target from Brokerages
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) have received an average rating of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average […] - 2025-03-11 03:58:52
New York State Common Retirement Fund Reduces Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)
New York State Common Retirement Fund lessened its holdings in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) by 23.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 3,902 shares of the company’s stock after selling 1,200 shares during the quarter. New York State Common Retirement Fund’s holdings in Cartesian Therapeutics […] - 2025-03-07 06:33:08
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average PT from Brokerages
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The […] - 2025-02-12 04:10:51

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) RNAC holdings

DateNumber of RNAC Shares HeldBase Market Value of RNAC SharesLocal Market Value of RNAC SharesChange in RNAC Shares HeldChange in RNAC Base ValueCurrent Price per RNAC Share HeldPrevious Price per RNAC Share Held
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RNAC by Blackrock for IE00BYXG2H39

Show aggregate share trades of RNAC

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-06BUY14410.00010.340 10.306USD 1,484 13.18
2025-10-03BUY33610.19010.480 10.451USD 3,512 13.20
2025-10-02BUY4810.34010.345 10.345USD 497 13.22
2025-09-30BUY9610.22010.488 10.461USD 1,004 13.25
2025-09-26BUY969.2609.500 9.476USD 910 13.29
2025-09-25BUY969.4609.990 9.937USD 954 13.31
2025-09-24BUY110.07010.120 10.115USD 10 13.33
2025-09-18BUY4710.31010.460 10.445USD 491 13.35
2025-09-17BUY1449.15010.000 9.915USD 1,428 13.37
2025-09-11SELL-489.96010.180 10.158USD -488 13.45 Profit of 158 on sale
2025-09-10BUY969.81010.250 10.206USD 980 13.47
2025-09-05SELL-4810.64010.830 10.811USD -519 13.53 Profit of 131 on sale
2025-08-29SELL-14410.05010.350 10.320USD -1,486 13.62 Profit of 475 on sale
2025-08-27BUY9410.62510.830 10.809USD 1,016 13.66
2025-08-26SELL-4710.78011.340 11.284USD -530 13.67 Profit of 112 on sale
2025-08-25BUY4711.25011.385 11.372USD 534 13.69
2025-08-20SELL-18811.07011.200 11.187USD -2,103 13.72 Profit of 477 on sale
2025-08-18BUY9411.28011.560 11.532USD 1,084 13.76
2025-08-08SELL-9410.53010.825 10.795USD -1,015 13.84 Profit of 286 on sale
2025-08-05BUY4611.83012.570 12.496USD 575 13.90
2025-08-01SELL-13812.33013.100 13.023USD -1,797 13.92 Profit of 123 on sale
2025-07-30BUY18412.85013.960 13.849USD 2,548 13.93
2025-07-17SELL-9212.53013.570 13.466USD -1,239 14.00 Profit of 49 on sale
2025-07-11SELL-37613.32013.630 13.599USD -5,113 14.02 Profit of 159 on sale
2025-07-07BUY14110.77011.180 11.139USD 1,571 14.08
2025-07-02BUY2,58511.37011.750 11.712USD 30,276 14.14
2025-06-25BUY9410.76010.870 10.859USD 1,021 14.25
2025-06-11BUY9410.41011.260 11.175USD 1,050 14.63
2025-06-10BUY9410.77011.310 11.256USD 1,058 14.67
2025-06-04SELL-479.54010.010 9.963USD -468 14.84 Profit of 229 on sale
2025-04-23BUY4711.63011.970 11.936USD 561 16.56
2025-04-10SELL-37610.36010.980 10.918USD -4,105 17.31 Profit of 2,404 on sale
2025-04-08SELL-479.52011.490 11.293USD -531 17.53 Profit of 293 on sale
2025-04-07SELL-4710.11010.210 10.200USD -479 17.64 Profit of 350 on sale
2025-04-04SELL-23510.00012.100 11.890USD -2,794 17.77 Profit of 1,381 on sale
2025-04-01BUY1,90212.49013.660 13.543USD 25,759 17.94
2025-03-31SELL-12613.18014.452 14.325USD -1,805 18.02 Profit of 465 on sale
2025-03-14SELL-67215.80016.750 16.655USD -11,192 18.65 Profit of 1,339 on sale
2025-03-07SELL-8218.40018.760 18.724USD -1,535 18.76 Profit of 3 on sale
2025-03-04SELL-4217.84017.860 17.858USD -750 18.82 Profit of 41 on sale
2025-02-25BUY8419.07019.500 19.457USD 1,634 18.90
2025-02-19SELL-4119.34019.785 19.740USD -809 18.85 Loss of -37 on sale
2025-02-13BUY12319.03019.390 19.354USD 2,381 18.76
2025-02-12BUY4118.92019.100 19.082USD 782 18.75
2025-02-11BUY16418.52018.560 18.556USD 3,043 18.76
2025-01-17BUY16419.29019.610 19.578USD 3,211 17.73
2025-01-16BUY16418.93020.120 20.001USD 3,280 17.56
2025-01-10SELL-8216.84017.170 17.137USD -1,405 16.92 Loss of -18 on sale
2025-01-08SELL-16416.92017.255 17.221USD -2,824 16.93 Loss of -48 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RNAC

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1916,272030,37253.6%
2025-09-1813,730038,35235.8%
2025-09-1714,577030,91247.2%
2025-09-168,546015,74954.3%
2025-09-1525,249041,79260.4%
2025-09-1210,062024,88640.4%
2025-09-1112,777026,24848.7%
2025-09-105,810018,33531.7%
2025-09-095,589017,46532.0%
2025-09-085,082016,14431.5%
2025-09-053,26208,28939.4%
2025-09-048,648014,72958.7%
2025-09-037,635017,42543.8%
2025-09-029,875033,92229.1%
2025-08-297,103012,40857.2%
2025-08-286,832022,19830.8%
2025-08-276,315015,02042.0%
2025-08-267,742015,93248.6%
2025-08-257,36860011,35064.9%
2025-08-227,002026,91726.0%
2025-08-215,515035,94115.3%
2025-08-2017,445027,93962.4%
2025-08-1910,511021,06349.9%
2025-08-1821,838039,50155.3%
2025-08-1510,970022,61948.5%
2025-08-146,34608,12878.1%
2025-08-1311,868020,24458.6%
2025-08-129,717014,44367.3%
2025-08-1114,6268019,82373.8%
2025-08-087,274012,68357.4%
2025-08-0710,825018,86257.4%
2025-08-0610,2363219,23053.2%
2025-08-0511,918024,44748.8%
2025-08-047,187010,43068.9%
2025-08-0119,643027,33371.9%
2025-07-3116,413022,92871.6%
2025-07-3024,706046,49853.1%
2025-07-299,529013,92468.4%
2025-07-2812,6691722,70255.8%
2025-07-2512,32220015,75978.2%
2025-07-249,272014,13465.6%
2025-07-2315,2900103,81714.7%
2025-07-2210,028018,80453.3%
2025-07-2115,8596021,28074.5%
2025-07-1812,310019,19364.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy